Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Editas Medicine Inc shares valued at $769 were sold by Parison Amy on Jun 03 ’25. At $1.72 per share, Parison Amy sold 446 shares. The insider’s holdings dropped to 17,506 shares worth approximately $38163.08 following the completion of this transaction.
Also, Burkly Linda sold 726 shares, netting a total of over 1,252 in proceeds. Following the sale of shares at $1.72 each, the insider now holds 69,519 shares.
Before that, O’Neill Gilmore Neil had sold 15,192 shares from its account. In a trade valued at $26,196, the CEO traded Editas Medicine Inc shares for $1.72 each. Upon closing the transaction, the insider’s holdings decreased to 15,192 shares, worth approximately $0.61 million.
As published in their initiating research note from H.C. Wainwright on April 28, 2025, Editas Medicine Inc [EDIT] has been a Buy and the price target has been revised to $3. Analysts at JP Morgan downgraded the stock from ‘”a Neutral”‘ to ‘”an Underweight”‘ outlook in a report released in mid December. As of December 13, 2024, Truist has decreased its “Buy” rating to a “Hold” for EDIT. Earlier on December 13, 2024, Stifel downgraded its rating. Their new recommendation was “a Hold” for EDIT stock which previously was a “a Buy”.
Analyzing EDIT Stock Performance
During the last five days, there has been a surge of approximately 21.11%. Over the course of the year, Editas Medicine Inc shares have jumped approximately 71.65%. Shares of the company reached a 52-week high of $3.30 on 02/19/25 and a 52-week low of $0.91 on 04/07/25.
Support And Resistance Levels for Editas Medicine Inc (EDIT)
According to the 24-hour chart, there is a support level at 2.00, which, if violated, would cause prices to drop to 1.82. In the upper region, resistance lies at 2.33. The next price resistance is at 2.48. RSI (Relative Strength Index) is 69.70 on the 14-day chart, showing neutral technical sentiment.
